Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult patients with mild, moderate, and severe hidradenitis suppurativa; A single-centre, prospective, single arm, investigator-initiated clinical trial with 16 weeks twice times daily oral treatment

Next Previous
X
Search
Trial Profile

Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult patients with mild, moderate, and severe hidradenitis suppurativa; A single-centre, prospective, single arm, investigator-initiated clinical trial with 16 weeks twice times daily oral treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Orismilast (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OSIRIS

    • Most Recent Events

    • 09 May 2024 Status changed from recruiting to completed as per results published in the Journal of the European Academy of Dermatology and Venereology.
    • 01 May 2024 Results examining tolerability, safety and efficacy of oral phosphodiesterase-4 (PDE4) inhibitior orismilast 10-40 mg twice daily (BID) in HS published in the Journal of the European Academy of Dermatology and Venereology
    • 15 Mar 2024 According to an UNION Therapeutics media release, data from the study were presented in the Journal of the European Academy of Dermatology and Venereology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top